Hypofractionated partial breast re-irradiation in the conservative retreatment of breast cancer local recurrence.

breast cancer external beam radiotherapy local recurrence partial breast irradiation reirradiation retreatment

Journal

Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 23 04 2024
revised: 24 06 2024
accepted: 02 07 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 28 7 2024
Statut: aheadofprint

Résumé

to evaluate the outcome of partial breast re-irradiation (re-PBI) with intensity modulated RT (IMRT), using a hypofractionated scheme for breast cancer (BC) local recurrence (LR) operated on with repeat breast-conserving surgery (re-BCS). IMRT-based re-PBI was performed using either helical or step-and-shoot modality to deliver 37.05 Gy in 13 fractions in 2.5 weeks. Cumulative incidence (CumI) of 2ndLR, toxicity, disease-free (DFS), BC specific (BCSS), and overall (OS) survival were evaluated. Between 5/2012 and 5/2021, 70 patients had re-PBI. Median follow-up (FU) was 6.3 years (Q1-Q3, 4.0-8.1.). Median age at 1stLR was 62. The median primary BC-1stLR interval was 12.4 years (range: 1.6-26.7). Luminal A-like 1stLR accounted for 41% of the cases and median size was 0.8 cm. During FU, 18 (26%) patients showed a subsequent event: three 2snLRs (corresponding to 8-y Cumulative rate of 4%), 3 regional nodal recurrences, 7 distant metastases, and 5 other primary tumors. At 8 years, DFS, BCSS and OS were 76%, 90%, and 90%, respectively. At multivariate analysis, Grade 3 and extensive intraductal component were independent predictors for DFS. For 51 and 46 patients, chronic toxicity and cosmesis were evaluated, respectively: 4% had grade 3 fibrosis and cosmesis was deemed good/excellent in just over 60% of the cases. Re-PBI after re-BCS represents a feasible alternative to mastectomy with regard to local control, showing an acceptable toxicity profile. A long-term FU is crucial to better understand the pattern of relapse and consolidate the position of re-PBI in clinical practice.

Identifiants

pubmed: 39069002
pii: S1879-8500(24)00164-4
doi: 10.1016/j.prro.2024.07.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Maria Cristina Leonardi (MC)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Simona Arculeo (S)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Samuele Frassoni (S)

Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.

Maria Alessia Zerella (MA)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Marianna Alessandra Gerardi (MA)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Cristiana Fodor (C)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Paolo Veronesi (P)

Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; Division of Breast Surgery, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Viviana Enrica Galimberti (VE)

Division of Breast Surgery, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Francesca Magnoni (F)

Division of Breast Surgery, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Ekaterina Milovanova (E)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.

Damaris Patricia Rojas (DP)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Samantha Dicuonzo (S)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Anna Morra (A)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Mattia Zaffaroni (M)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Maria Giulia Vincini (MG)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Federica Cattani (F)

Unit of Medical Physics, European Institute of Oncology IRCCS, Milan, Italy.

Vincenzo Bagnardi (V)

Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.

Roberto Orecchia (R)

Scientific Directorate, European Institute of Oncology, IEO IRCCS, Milan, Italy.

Barbara Alicja Jereczek-Fossa (BA)

Division of Radiotherapy, European Institute of Oncology, IEO IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.

Classifications MeSH